Cell Culture – News and Features

Scientists have developed an advanced gene editor – the evoCAST – that can add long stretches of DNA to defined locations in the human genome without creating unwanted modifications.

Researchers have created a groundbreaking 3D-printed artificial tumor tissue capable of replicating the in vivo conditions of patient-derived cancer cells, which can be used to predict prognosis.

Researchers have completed the full genome of the northern white rhinoceros, aiding efforts to rescue the functionally extinct species. The high-quality reference genome enables quality control of stem cells intended to create sperm and eggs.

Researchers have identified that the balance between two proteins – STAT3 and STAT5 – is important for making tumors vulnerable to immune checkpoint therapy and targeting STAT3 degradation is a potential novel cancer immunotherapy strategy.

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The protective effect was enhanced by delivering the antibody in a nasal spray.

A new study shows AI can design synthetic DNA to precisely control gene expression in healthy mammalian cells. The model created custom enhancers from scratch, enabling selective gene activation or suppression in blood cell types.

Researchers have developed a new precision tool for manipulating mitochondrial DNA. The method shows potential for improving research models and as a potential therapeutic strategy for treating mitochondrial diseases.

This article explores how synthetic biology is revolutionizing therapeutics through engineered cells, precision genetic circuits and AI-driven design, with applications in cancer treatment, vaccine development and next-generation immunotherapies.

Researchers have developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure. The injectable protein-like polymer intervenes in the body’s response to stress and inflammation.

Portal Bio’s microfluidic technology enhances drug discovery and cell engineering by enabling efficient, scalable molecular delivery for sensitive cell types.